Physician profile
Javier N Chacon
NPI 1154383008
$12,875.85
in general payments reported to CMS, 2019-2025
38 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,439 · 2020: $1,849 · 2021: $2,143 · 2022: $1,756 · 2023: $2,196 · 2024: $1,816 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,688.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,486.42 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,316.39 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $1,235.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,031.40 | 2019-2025 | Rybelsus, Ozempic |
| Abbvie INC. | $950.67 | 2019-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $936.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $880.40 | 2021-2025 | |
| Exact Sciences Corporation | $571.02 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $468.64 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $424.45 | 2019-2025 | Verquvo, Lagevrio, Steglatro |
| Ironwood Pharmaceuticals, INC | $390.48 | 2021-2024 | Linzess |
| Amgen INC. | $337.88 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $327.71 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $295.91 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $271.14 | 2019-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $269.03 | 2023-2025 | Ibsrela |
| Abbott Laboratories | $263.18 | 2021-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $228.64 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $220.04 | 2019-2022 | |
| Allergan, INC. | $141.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $120.70 | 2024-2025 | Voquezna |
| Esperion Therapeutics, INC. | $102.78 | 2020-2024 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $102.55 | 2019-2025 | Zoryve |
| Nestle Healthcare Nutrition INC. | $80.40 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $68.15 | 2022-2023 | |
| Dexcom, INC. | $53.78 | 2022-2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $47.76 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $47.74 | 2023 | Onpattro |
| Corcept Therapeutics | $39.49 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $24.45 | 2025 | Symbravo |
| Boston Scientific Corporation | $22.44 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $20.50 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $20.00 | 2025 | Evkeeza |
| Xeris Pharmaceuticals, INC. | $18.59 | 2024 | Gvoke Hypopen |
| Ibsa Pharma INC. | $17.40 | 2025 | Licart, Flector, Tirosint |
| Daiichi Sankyo INC. | $16.13 | 2024 | Injectafer |
| Astellas Pharma US INC | $13.64 | 2019 | |
| Alfasigma USA, INC. | $12.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Chacon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.